By further verification of candidate serum markers with a larger sample of sera (174 ESCC patients and 189 normal controls), we found that serum eotaxin and IP‐10 might be potential biomarkers in the diagnosis and therapeutic monitoring of ESCC patients. Here, CXCL10 is linked to esophageal squamous cell carcinoma.